Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.

Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW.

Genes Dev. 1999 Apr 15;13(8):1015-24.

2.

Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation.

Leo E, Welsh K, Matsuzawa S, Zapata JM, Kitada S, Mitchell RS, Ely KR, Reed JC.

J Biol Chem. 1999 Aug 6;274(32):22414-22.

3.

Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis.

Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J.

EMBO J. 2001 Mar 15;20(6):1271-80.

4.

Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling.

Hostager BS, Haxhinasto SA, Rowland SL, Bishop GA.

J Biol Chem. 2003 Nov 14;278(46):45382-90. Epub 2003 Sep 4.

6.

Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent.

Manning E, Pullen SS, Souza DJ, Kehry M, Noelle RJ.

Eur J Immunol. 2002 Jan;32(1):39-49.

7.

TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses.

Nguyen LT, Duncan GS, Mirtsos C, Ng M, Speiser DE, Shahinian A, Marino MW, Mak TW, Ohashi PS, Yeh WC.

Immunity. 1999 Sep;11(3):379-89.

8.
9.

Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice.

Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J.

Genes Cells. 1999 Jun;4(6):353-62.

10.
11.

TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages.

Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl LM, Suttles J.

J Immunol. 2005 Jan 15;174(2):1081-90.

12.
13.
14.

Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signaling.

Shembade N, Harhaj NS, Liebl DJ, Harhaj EW.

EMBO J. 2007 Sep 5;26(17):3910-22. Epub 2007 Aug 16.

15.

Sensitivity of TLR4- and -7-induced NF kappa B1 p105-TPL2-ERK pathway to TNF-receptor-associated-factor-6 revealed by RNAi in mouse macrophages.

Loniewski KJ, Patial S, Parameswaran N.

Mol Immunol. 2007 Jul;44(15):3715-23. Epub 2007 May 15.

PMID:
17507094
16.

A novel zinc finger protein that inhibits osteoclastogenesis and the function of tumor necrosis factor receptor-associated factor 6.

Shin JN, Kim I, Lee JS, Koh GY, Lee ZH, Kim HH.

J Biol Chem. 2002 Mar 8;277(10):8346-53. Epub 2001 Dec 20.

17.

Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.

Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J.

J Bone Miner Res. 2004 Nov;19(11):1905-16. Epub 2004 Sep 27.

18.

Competition between TRAF2 and TRAF6 regulates NF-kappaB activation in human B lymphocytes.

Zhang W, Zhang X, Wu XL, He LS, Zeng XF, Crammer AC, Lipsky PE.

Chin Med Sci J. 2010 Mar;25(1):1-12.

PMID:
20449947
19.

Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a ras-independent pathway.

Kashiwada M, Shirakata Y, Inoue JI, Nakano H, Okazaki K, Okumura K, Yamamoto T, Nagaoka H, Takemori T.

J Exp Med. 1998 Jan 19;187(2):237-44.

Items per page

Supplemental Content

Write to the Help Desk